Stockreport

Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Akero Therapeutics, Inc.  (AKRO) 
Last akero therapeutics, inc. earnings: 3/16 07:30 am Check Earnings Report
PDF — First patients dosed in Phase 3 SYNCHRONY Outcomes study of lead candidate efruxifermin (EFX) in patients with compensated cirrhosis (F4) due to MASH — — Phase 3 SYNC [Read more]